<article>
<section>
<h1 id="header">Quantitative <i>in vivo</i> assessment of amyloid-beta phagocytic capacity in an Alzheimer’s disease mouse model</h1>
<p><time datetime="2021-01-15">Published: January 15, 2021</time></p>
<p>Shun-Fat Lau,<sup><a href="#aff1">1</a>,<a href="#aff2">2</a>,<a href="#fn1">4</a></sup> Wei Wu,<sup><a href="#aff1">1</a>,<a href="#aff2">2</a></sup> Heukjin Seo,<sup><a href="#aff1">1</a>,<a href="#aff2">2</a></sup> Amy K.Y. Fu,<sup><a href="#aff1">1</a>,<a href="#aff2">2</a>,<a href="#aff3">3</a></sup> and Nancy Y. Ip<sup><a href="#aff1">1</a>,<a href="#aff2">2</a>,<a href="#aff3">3</a>,<a href="#fn2">5</a>,<a href="#cor1">*</a></sup></p>
<p id="aff1"><sup>1</sup>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China</p>
<p id="aff2"><sup>2</sup>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China</p>
<p id="aff3"><sup>3</sup>Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development, HKUST Shenzhen Research Institute, Shenzhen–Hong Kong Institute of Brain Science, Shenzhen, Guangdong 518057, China</p>
<p id="fn1"><sup>4</sup>Technical contact</p>
<p id="fn2"><sup>5</sup>Lead contact</p>
<p id="cor1"><sup>*</sup>Correspondence: <a href="mailto:boip@ust.hk">boip@ust.hk</a></p>
<p><span class="open-access">Open Access</span> • DOI: <a href="https://doi.org/10.1016/j.xpro.2020.100265">10.1016/j.xpro.2020.100265</a></p>
</section>
<section>
<h2 id="summary">Summary</h2>
<p>Alzheimer’s disease is characterized by the deposition of extracellular amyloid-beta (Aβ) plaques. While microglial phagocytosis is a major mechanism through which Aβ is cleared, there is no method for quantitatively assessing Aβ phagocytic capacity of microglia <i>in vivo</i>. Here, we present a flow cytometry-based method for investigating the Aβ phagocytic capacity of microglia <i>in vivo</i>. This method enables the direct comparison of Aβ phagocytic capacity between different microglial subpopulations as well as the direct isolation of Aβ phagocytic microglia for downstream applications.</p>
<p>For complete details on the use and execution of this protocol, please refer to <a href="#bib2">Lau et al. (2020)</a>.</p>




<div class="highlights">
<h3>Highlights</h3>
<ul>
<li>Detailed protocol for quantitative assessment of Aβ phagocytosis <i>in vivo</i>
</li>
<li>Optimized sample preparation for isolating abundant and highly viable microglia</li>
<li>High-throughput analysis of microglial phagocytic capacity within 1 day</li>
<li>Compatible with downstream transcriptomic and proteomic analyses</li>
</ul>
</div>
<div class="graphical-abstract">
<h3>Graphical Abstract</h3>
<figure><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/372-GA.jpg" alt="GraphicalAbstract.jpg"></figure>
</div></section>
<section>
<h2 id="before-you-begin">Before you begin</h2>
<div class="timing">
<span class="timing-title">Timing:</span> 1–1.5 h</div>
<p>This section lists the stock and working solutions needed for the experiment. It is strongly recommended to prepare the working solution immediately before the experiments.</p>
<ol>
<li>Prepare methoxy-X04 (MeX04) solution
<ol type="a">
<li>Stock solution (10 mg/mL): Prepare MeX04 stock solution (10 mg/mL) by dissolving in DMSO and storing in aliquots (200 μL) at −80°C for at least 1 year.</li>
<li>Working solution (2 mg/mL): Dilute 2 parts MeX04 stock in 3 parts DMSO and 5 parts 0.9% saline (pH 12.0). Refer to “<a href="#materials-and-equipment">Materials and equipment</a>” for detailed recipe for dilution.</li>
</ol>
</li>
<li>Prepare artificial cerebrospinal fluid (aCSF) for brain dissociation
<ol type="a">
<li>aCSF stock solution (10×, without bicarbonate and glucose): Refer to “<a href="#materials-and-equipment">Materials and equipment</a>” for detailed recipe.</li>
<li>aCSF working solution (1×): Refer to “<a href="#materials-and-equipment">Materials and equipment</a>” for detailed recipe for dilution.</li>
</ol>
</li>
<li>Enzyme dissociation solution (20 mL per reaction, freshly prepared)
<ol type="a">
<li>Refer to “<a href="#materials-and-equipment">Materials and equipment</a>” for detailed recipe.</li>
</ol>
</li>
<li>Isotonic Percoll (stock at 4°C)
<ol type="a">
<li>Refer to “<a href="#materials-and-equipment">Materials and equipment</a>” for detailed recipe.</li>
</ol>
</li>
</ol>
</section>
<section>
<h2 id="key-resources-table">Key resources table</h2>
<table id="krt">
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="3">Antibodies</td>
</tr>
<tr>
<td>Rat anti-CD11b (M1/70) APC</td>
<td>eBioscience</td>
<td>Cat. #17-0112-83</td>
</tr>
<tr>
<td>Rat anti-CD45 (30-F11) FITC</td>
<td>eBioscience</td>
<td>Cat. #11-0451-85</td>
</tr>
<tr>
<td colspan="3">Chemicals, peptides, and recombinant proteins</td>
</tr>
<tr>
<td>Methoxy-X04</td>
<td>Tocris Bioscience</td>
<td>Cat. #4920</td>
</tr>
<tr>
<td>Papain</td>
<td>Worthington Biochemical</td>
<td>Cat. #LS003126</td>
</tr>
<tr>
<td>DNaseI</td>
<td>Worthington Biochemical</td>
<td>Cat. #LS002140</td>
</tr>
<tr>
<td>
<span class="small-caps">l</span>-Cysteine</td>
<td>Sigma-Aldrich</td>
<td>Cat. #168149</td>
</tr>
<tr>
<td>Percoll</td>
<td>Sigma-Aldrich</td>
<td>Cat. #P1644</td>
</tr>
<tr>
<td>HBSS (10×), no calcium, no magnesium, no phenol red</td>
<td>Thermo Fisher</td>
<td>Cat. #14185052</td>
</tr>
<tr>
<td>DMEM/F-12, no phenol red</td>
<td>Thermo Fisher</td>
<td>Cat. #21041025</td>
</tr>
<tr>
<td>Fetal bovine serum</td>
<td>Corning</td>
<td>Cat. #35-079-CV</td>
</tr>
<tr>
<td>Dimethyl sulfoxide</td>
<td>Sigma-Aldrich</td>
<td>Cat. #472301</td>
</tr>
<tr>
<td colspan="3">Experimental models: organisms/strains</td>
</tr>
<tr>
<td>APP/PS1 mice (non-transgenic mice as WT mice control)</td>
<td>The Jackson Laboratory</td>
<td>Cat. #34829-JAX</td>
</tr>
<tr>
<td colspan="3">Software and algorithms</td>
</tr>
<tr>
<td><i>FlowJo</i></td>
<td>TreeStar</td>
<td><a href="https://www.flowjo.com">https://www.flowjo.com</a></td>
</tr>
<tr>
<td colspan="3">Other</td>
</tr>
<tr>
<td>Hemocytometer</td>
<td>Sigma</td>
<td>Cat. #Z359629</td>
</tr>
<tr>
<td>BD Influx Cell Sorter</td>
<td>BD Biosciences</td>
<td>n/a</td>
</tr>
</tbody>
</table>
</section>
<section>
<h2 id="materials-and-equipment">Materials and equipment</h2>
<table id="undtbl1">
<caption>MeX04 working solution (for 3 injections, freshly prepared)</caption>
<thead>
<tr>
<th>Reagent</th>
<th>Final concentration</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MeX04 stock (10 mg/mL)</td>
<td>2 mg/mL</td>
<td>200 μL</td>
</tr>
<tr>
<td>DMSO</td>
<td>n/a</td>
<td>300 μL</td>
</tr>
<tr>
<td>0.9% saline, pH 12.0</td>
<td>n/a</td>
<td>500 μL</td>
</tr>
<tr>
<td><b>Total</b></td>
<td>n/a</td>
<td>1,000 μL</td>
</tr>
</tbody>
</table>
<div class="critical">
<span class="critical-title">Critical:</span> Protect from light. Avoid repeated freeze-thaw of MeX04 stock. The resultant MeX04 working solution (2 mg/mL) should be yellow.</div>
<table id="undtbl2">
<caption>aCSF stock solution (10×, stock at 4°C for at least 1 month)</caption>
<thead>
<tr>
<th>Reagent</th>
<th>Final concentration</th>
<th>Amount or volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaCl</td>
<td>1190 mM</td>
<td>34.77 g</td>
</tr>
<tr>
<td>KCl</td>
<td>25 mM</td>
<td>0.93 g</td>
</tr>
<tr>
<td>CaCl<sub>2</sub>⋅2H<sub>2</sub>O</td>
<td>25 mM</td>
<td>1.84 g</td>
</tr>
<tr>
<td>NaH<sub>2</sub>PO<sub>4</sub>⋅2H<sub>2</sub>O</td>
<td>10 mM</td>
<td>0.78 g</td>
</tr>
<tr>
<td>MgCl<sub>2</sub>⋅6H<sub>2</sub>O</td>
<td>13 mM</td>
<td>1.32 g</td>
</tr>
<tr>
<td>Autoclaved deionized H<sub>2</sub>O</td>
<td>n/a</td>
<td>To 500 mL</td>
</tr>
<tr>
<td><b>Total</b></td>
<td>n/a</td>
<td>500 mL</td>
</tr>
</tbody>
</table>
<table id="undtbl3">
<caption>aCSF working solution (1×, freshly prepared)</caption>
<thead>
<tr>
<th>Reagent</th>
<th>Final concentration</th>
<th>Amount or volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>aCSF stock solution</td>
<td>1×</td>
<td>50 mL</td>
</tr>
<tr>
<td>NaHCO<sub>3</sub>
</td>
<td>26.2 mM</td>
<td>1.1 g</td>
</tr>
<tr>
<td>
<span class="small-caps">d</span>-Glucose</td>
<td>11.0 mM</td>
<td>0.991 g</td>
</tr>
<tr>
<td>Autoclaved deionized H<sub>2</sub>O</td>
<td>n/a</td>
<td>To 500 mL</td>
</tr>
<tr>
<td><b>Total</b></td>
<td>n/a</td>
<td>500 mL</td>
</tr>
</tbody>
</table>
<table id="undtbl4">
<caption>Enzyme dissociation solution (20 mL per reaction, freshly prepared)</caption>
<thead>
<tr>
<th>Reagent</th>
<th>Final concentration</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>aCSF working solution</td>
<td>1×</td>
<td>19.8 mL</td>
</tr>
<tr>
<td>Papain (1,000 U/mL)</td>
<td>5 U/mL</td>
<td>100 μL</td>
</tr>
<tr>
<td>DNaseI (7,000 U/mL)</td>
<td>35 U/mL</td>
<td>100 μL</td>
</tr>
<tr>
<td>
<span class="small-caps">l</span>-Cysteine</td>
<td>1.65 mM</td>
<td>0.004 g</td>
</tr>
<tr>
<td><b>Total</b></td>
<td>N/A</td>
<td>20 mL</td>
</tr>
</tbody>
</table>
<table id="undtbl5">
<caption>Isotonic Percoll (stock at 4°C for at least 3 months)</caption>
<thead>
<tr>
<th>Reagent</th>
<th>Final concentration</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>10× HBSS</td>
<td>1×</td>
<td>5 mL</td>
</tr>
<tr>
<td>Percoll</td>
<td>n/a</td>
<td>45 mL</td>
</tr>
<tr>
<td><b>Total</b></td>
<td>n/a</td>
<td>50 mL</td>
</tr>
</tbody>
</table>
</section>
<section>
<h2 id="step-by-step-method-details">Step-by-step method details</h2>
<h3 id="sec3.1">
<i>In vivo</i> labeling of amyloid plaques</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 3 h</div>
<p>This section describes how to label amyloid plaques with methoxy-X04 (MeX04), a blood–brain barrier-penetrating amyloid-beta (Aβ) dye. After MeX04 is intraperitoneally injected into Alzheimer’s disease (AD) transgenic mice, it enters the brain and binds to the surface of Aβ plaques. If microglia are actively phagocytosing amyloid plaques, MeX04 will be internalized together with Aβ. Thus, subsequent flow cytometry analysis enables the quantification of the capacity of microglia to phagocytose Aβ within the 3 h interval between MeX04 injection and sacrifice.</p>
<ol>
<li>Intraperitoneal injection of MeX04 into 6–18-month-old AD transgenic mice
<ol type="a">
<li>Warm the MeX04 working solution (2 mg/mL) in a 37°C water bath for 5 min before injection.</li>
<li>Weigh the AD transgenic mice and intraperitoneally inject MeX04 working solution at 10 mg/kg.</li>
</ol>
</li>
</ol>
<div class="note">
<span class="note-title">Note:</span> Also include non-transgenic wild-type (WT) mice (i.e., without amyloid plaques) to control for MeX04 signal baseline in flow cytometry analysis.</div>
<h3 id="sec3.2">Brain dissociation and microglia isolation</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 3–4 h</div>
<p>This section describes a modified protocol to maximize the number of microglia isolated.</p>
<div class="critical">
<span class="critical-title">Critical:</span> To achieve a high yield of viable microglia, freshly prepared aCSF with pH 7.2–7.4 and gentle mechanical dissociation are essential. It is also recommended that each experimenter handle fewer than 3 samples to minimize differences in digestion time.</div>
<ol start="2">
<li>Brain dissection
<ol type="a">
<li>Euthanize mice using isoflurane 3 h after MeX04 injection and perfuse mice with 20 mL ice-cold PBS.</li>
<li>Dissect the region(s) of interest in ice-cold PBS.</li>
</ol>
</li>
<li>Brain dissociation by papain
<ol type="a">
<li>Prepare enzyme dissociation solution by adding 0.004 g <span class="small-caps">l</span>-cysteine, 100 U papain, and 700 U DNaseI into 20 mL working aCSF solution (refer to “<a href="#materials-and-equipment">Materials and equipment</a>” for detailed recipe).</li>
<li>Prewarm the enzyme dissociation solution in a 37°C water bath for 5 min.</li>
<li>Mince the brain tissue into small pieces on a petri dish and transfer to a 50-mL falcon tube with 20 mL enzyme dissociation solution.</li>
<li>Incubate in a 37°C water bath with constant shaking for 10 min.</li>
<li>Remove the tube from the water bath and let the undigested tissue sink to the bottom.</li>
<li>Very gently pass the tissue through a 20-gauge needles 3 times and return the tubes to the 37°C water bath for an additional 30 min of digestion.</li>
<li>Pellet the cells by centrifugation at 800 × <i>g</i> at 4°C for 5 min.</li>
<li>Aspirate the supernatant and subject it to a Percoll gradient.</li>
</ol>
</li>
<li>Percoll gradient
<ol type="a">
<li>Prepare isotonic Percoll by adding 9 parts Percoll into 1 part 10× HBSS.</li>
<li>Resuspend the cell pellet in 7 mL working aCSF solution.</li>
<li>Add 3 mL isotonic Percoll and mix well by inverting 10 times; the resultant solution contains 30% Percoll.</li>
<li>Gently add 2 mL working aCSF on top.</li>
<li>Centrifuge at 800 × <i>g</i> at 4°C for 15 min with the slowest acceleration and zero deceleration.</li>
<li>Use a P1000 pipette to gently remove the myelin debris layer trapped between the aCSF and 30% Percoll, and subsequently aspirate all supernatant (<a href="#fig1">Figure 1</a>).
<figure id="fig1"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/372-Fig1.jpg" alt="Fig1.jpg">
<figcaption>
<div class="figcaption-title">Figure 1. Photograph of the myelin layer and cell pellet after Percoll gradient centrifugation</div>
<p>The myelin layer is trapped between the 30% Percoll layer and artificial cerebrospinal fluid layer.</p>
</figcaption>
</figure>
</li>
<li>Resuspend the cell pellet in 200 μL of ice-cold DMEM/F12 with 10% heat-inactivated FBS.</li>
</ol>
</li>
</ol>
<ol start="5">
<li>Cell staining
<ol type="a">
<li>Before cell staining, aliquot 5 μL cell suspension and inspect cell viability, number, and singlet by hemocytometer.
<div class="note">
<span class="note-title">Note:</span> Number of viable cell number ranges from 1.5–3.0 × 10<sup>6</sup> per forebrain depending on age of AD transgenic mice.</div>
</li>
<li>To label microglia, stain the cell suspension (200 μL) with CD11b-APC (1:200) and CD45-FITC (1:200) for 45 min at 4°C with rotation. In addition, prepare unstained controls using AD transgenic model mice and non-transgenic wild-type mice to serve as fluorescence-minus-one controls.
<div class="note">
<span class="note-title">Note:</span> The emission spectrum of MeX04 overlaps with that of DAPI/Pacific blue.</div>
</li>
<li>After 45 min, wash the cells with 1 mL DMEM/F12 + 10% FBS and centrifuge at 800 × <i>g</i> at 4°C for 5 min.</li>
<li>Resuspend the cells in 500 μL DMEM/F12 + 10% FBS.</li>
</ol>
</li>
</ol>
<ol start="6">
<li>Flow cytometry
<ol type="a">
<li>Switch on the flow cytometer and perform machine start-up.</li>
<li>Create the following plots in the template (<a href="#fig2">Figures 2</a>A and 2B)
<figure id="fig2"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/372-Fig2.jpg" alt="Fig2.jpg">
<figcaption>
<div class="figcaption-title">Figure 2. Gating strategy and analysis of Aβ phagocytic microglia in APP/PS1 transgenic mice</div>
<p>(A) Gating strategy to identify CD11b<sup>+</sup> CD45<sup>lo</sup> microglia. SSC, side-scattered.</p>
<p>(B) Contour plots showing the proportion of Aβ phagocytic microglia in 16-month-old APP/PS1 mice (an Alzheimer’s disease transgenic mouse model). Age-matched non-transgenic wild-type (WT) mice, which lack MeX04 signal, are used as control.</p>
<p>(C) Histogram showing the MeX04 signal intensity of Aβ phagocytic microglia (i.e., MeX04<sup>+</sup> microglia) and non-Aβ phagocytic microglia (i.e., MeX04<sup>−</sup> microglia). MFI, mean fluorescence intensity.</p>
</figcaption>
</figure>
<ol type="i">
<li>Side-scattered (SSC) versus forward-scattered (FSC) (to identify cell populations)</li>
<li>Pulse width trigger versus FSC (to identify singlets)</li>
<li>PB488 versus FSC-A (to identify CD45 signal)</li>
<li>PB660 versus FSC-A (to identify CD11b signal)</li>
<li>PB450 versus PB660 (to identify MeX04 signal)</li>
</ol>
</li>
<li>Use a non-transgenic mice brain sample to set a negative signal for MeX04 and an unstained control sample to set a negative signal for CD11b and CD45.</li>
<li>Proceed with the samples and record the MeX04 signals of 10,000 microglia.</li>
<li>Analyze the data using FlowJo to obtain the following:
<ol type="i">
<li>Proportion of MeX04<sup>+</sup> microglia = proportion of Aβ phagocytic microglia (<a href="#fig2">Figure 2</a>B)</li>
<li>Mean fluorescence intensity of MeX04 = Aβ phagocytic capacity (<a href="#fig2">Figure 2</a>C)</li>
</ol>
</li>
</ol>
</li>
</ol>
</section>
<section>
<h2 id="expected-outcomes">Expected outcomes</h2>
<p>This section describes some of the quality control steps during the protocol and the anticipated results. These steps are recommended to ensure good-quality results and minimize artifacts due to sample preparation.</p>
<h3 id="sec4.1">Cell number and viability after papain dissociation</h3>
<p>When starting with the whole forebrain, 2–3 million viable cells are routinely obtained after sample preparation. More importantly, the cell suspension should be mostly viable (&gt;95%) and singlet. After FACS isolation, approximately 150,000 microglia per 12-month-old APP/PS1 mouse are usually obtained; more if a younger mouse is used.</p>
<h3 id="sec4.2">Proportion of Aβ phagocytic microglia</h3>
<p>The proportion of Aβ phagocytic microglia varies among AD transgenic mouse models (e.g., APP/PS1 and 5xFAD mice) and with respect to mouse age. For APP/PS1 mice, the proportion of Aβ phagocytic microglia should be ∼10% and ∼20% at 12 and 16 months of age, respectively (<a href="#fig2">Figure 2</a>B) (<a href="#bib1">Fu et al., 2016</a>; <a href="#bib2">Lau et al., 2020</a>). This result has been further validated by immunohistochemistry (IHC) in the same APP/PS1 mice. Flow cytometry analysis showed that in 16-month-old APP/PS1 mice, 20.4 ± 2.8% of microglia are MeX04+ (n = 4; <a href="#fig2">Figure 2</a>B), whereas IHC analysis showed that 27.9 ± 4.0% of microglia are Aβ+ (n = 4; <a href="#fig3">Figure 3</a>). These results demonstrate the consistency of our method for examining the proportion of Aβ phagocytic microglia. Also, the intracellular localization of MeX04 in Aβ phagocytic microglia can be confirmed by confocal imaging (<a href="#fig4">Figure 4</a>).</p>
<figure id="fig3"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/372-Fig3.jpg" alt="Fig3.jpg">
<figcaption>
<div class="figcaption-title">Figure 3. Representative images showing the proportions of Aβ<sup>+</sup> microglia in 16-month-old APP/PS1 mice</div>
<p>Scale bar, 20 μm.</p>
</figcaption>
</figure>
<figure id="fig4"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/372-Fig4.jpg" alt="Fig4.jpg">
<figcaption>
<div class="figcaption-title">Figure 4. Intracellular MeX04 in FACS-isolated MeX04<sup>+</sup> microglia</div>
<p>Scale bar, 5 μm.</p>
</figcaption>
</figure>
</section>
<section>
<h2 id="limitations">Limitations</h2>
<p>This protocol only measures the phagocytic capacity of microglia within 1–2 h of MeX04 injection. It is inappropriate for long-term measurement (i.e., more than 4 h), because MeX04 can nonspecifically bind to nuclei or other non-Aβ materials.</p>
<p>Although this protocol is compatible with mechanical dissociation, there will be substantially more dead cells as a result of mechanical dissociation. The advantages and disadvantages of enzymatic dissociation versus mechanical dissociation are summarized below (<a href="#tbl1">Table 1</a>).</p>
<table id="tbl1">
<caption>Table 1. Advantages and disadvantages of using enzymatic and mechanical dissociation in this protocol</caption>
<thead>
<tr>
<th>Characteristic</th>
<th>Enzymatic dissociation</th>
<th>Mechanical dissociation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell viability</td>
<td>Higher</td>
<td>Lower</td>
</tr>
<tr>
<td>Proportion of Aβ phagocytic microglia</td>
<td>Higher (due to better cell viability; <a href="#fig5">Figure 5</a>)</td>
<td>Lower (due to poor cell viability; <a href="#fig5">Figure 5</a>)</td>
</tr>
<tr>
<td>Preservation of transcriptome</td>
<td>Potential induction of immediate early genes</td>
<td>Better</td>
</tr>
</tbody>
</table>
<figure id="fig5"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/372-Fig5.jpg" alt="Fig5.jpg">
<figcaption>
<div class="figcaption-title">Figure 5. Representative contour plots showing the proportions of Aβ phagocytic microglia after enzymatic or mechanical digestion</div>
<p>WT, non-transgenic wild-type.</p>
</figcaption>
</figure>
</section>
<section>
<h2 id="troubleshooting">Troubleshooting</h2>
<h3 id="sec6.1">Problem 1</h3>
<p>The MeX04 working solution appears cloudy (step 1a).</p>
<h3 id="sec6.2">Potential solutions</h3>
<p>Ensure that the 0.9% saline has the correct pH of 12.0.</p>
<p>Use new anhydrous DMSO.</p>
<p>Use a new MeX04 stock solution.</p>
<h3 id="sec6.3">Problem 2</h3>
<p>MeX04 cross-reacts with non-Aβ materials (step 1b).</p>
<h3 id="sec6.4">Potential solutions</h3>
<p>Titrate MeX04 for intraperitoneal injection and examine the specificity of the Aβ staining pattern by co-staining with Aβ antibody on brain sections.</p>
<h3 id="sec6.5">Problem 3</h3>
<p>There are few cells and/or poor viability after sample preparation (step 5a).</p>
<h3 id="sec6.6">Potential solutions</h3>
<p>Freshly prepare all buffers and bubble 5% CO<sub>2</sub> in O<sub>2</sub> through them for at least 10 min immediately before the experiment.</p>
<p>Gently mechanically dissociate with a 20-gauge needle; to avoid foaming, eject toward the tube wall.</p>
</section>
<section>
<h2 id="references">References</h2>
<p id="bib1">Fu, A.K.Y., Hung, K.W., Yuen, M.Y.F., Zhou, X., Mak, D.S.Y., Chan, I.C.W., Cheung, T.H., Zhang, B., Fu, W.Y., Liew, F.Y., et al. (2016). IL-33 ameliorates Alzheimer’s disease-like pathology and cognitive decline. Proc. Natl. Acad. Sci. U S A <i>113</i>, E2705-E2713.</p>
<p id="bib2">Lau, S.F., Chen, C., Fu, W.Y., Qu, J.Y., Cheung, T.H., Fu, A.K.Y., and Ip, N.Y. (2020). IL-33-PU.1 transcriptome reprogramming drives functional state transition and clearance activity of microglia in Alzheimer’s disease. Cell Rep. <i>31</i>, 107530.</p>
</section>
<section>
<h2 id="article-info">Article Info</h2>
<h3>Resource Availability</h3>
<h4>Lead contact</h4>
<p>Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Nancy Y. Ip (e-mail: <a href="mailto:boip@ust.hk">boip@ust.hk</a>).</p>
<h4>Materials availability</h4>
<p>This study did not generate new unique reagents.</p>
<h4>Data and code availability</h4>
<p>This study did not generate any unique datasets or code.</p>
<h3>Acknowledgments</h3>
<p>We thank all members of the Ip Laboratory for their many helpful discussions. This study was supported in part by the <a href="https://doi.org/10.13039/501100002920">Research Grants Council of Hong Kong</a> (the Collaborative Research Fund [C6027-19GF], the Theme-Based Research Scheme [T13-607/12R], and the General Research Fund [HKUST16149616, HKUST16103017, HKUST16100418, and HKUST16102019]), the <a href="https://doi.org/10.13039/501100012166">National Key R&amp;D Program of China</a> (2017YFE0190000 and 2018YFE0203600), the Areas of Excellence Scheme of the <a href="https://doi.org/10.13039/501100001839">University Grants Committee</a> (AoE/M-604/16), the <a href="https://doi.org/10.13039/501100003452">Innovation and Technology Commission</a> (ITCPD/17-9), the Guangdong Provincial Key S&amp;T Program (2018B030336001), and the Shenzhen Knowledge Innovation Program (JCYJ20180507183642005 and JCYJ20170413173717055). S.-F.L., W.W., and H.S. are recipients of the Hong Kong PhD Fellowship Award.</p>
<h3>Author Contributions</h3>
<p>S.-F.L., A.K.Y.F., and N.Y.I. conceived of the project; S.-F.L., W.W., and H.S. optimized and conducted the experiments; and S.-F.L., A.K.Y.F., and N.Y.I. wrote the manuscript.</p>
<h3>Declaration of Interests</h3>
<p>The authors declare no competing interests.</p>
</section>
</article>